drugset
drugset / Trial / NCT03950830

Disulfiram and Cisplatin in Refractory TGCTs.

NCT03950830 ↗

Phase 2 Completed 12 enrolled National Cancer Institute, Slovakia
NaSingle-groupOpen-labelTreatment

Summary

Non-randomized, open-label, single center trial to assess efficacy (as measured by overall response rate (ORR) by RECIST 1.1 of disulfiram and cisplatin in patients with multiple relapsed/refractory germ cell tumors (GCTs).

Timeline

Start
2019-05-14
Primary completion
2021-09-30
Completion
2022-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Disulfiram Small molecule 400 mg —

Indications

germ cell tumor